Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
Yale University
Summary
This study will examine the synaptotrophic effects of psilocybin among medically healthy, detoxified OUD subjects. Eligible OUD participants will undergo pre- and post- psilocybin administration PET scans with the \[11C\]-UCB-J radiotracer while inpatient.
Description
Participants will undergo screening as outpatients at the Clinical Neuroscience Research Unit (CNRU). Once deemed eligible, OUD subjects will be studied as inpatients. However, they will have the option of scheduling their second \[11C\]-UCB-J PET as an outpatient (pending these participants' agreement to undergo outpatient visits twice per week to provide urine toxicology to monitor abstinence before PET). The only portion of the study that will be available as outpatient for OUD subjects will be the 1-2 weeks before the second \[11C\]-UCB-J PET scan. The subject will still be admitted for 1…
Eligibility
- Age range
- 21–55 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Voluntary, written, informed consent; * Physically healthy by medical history, physical, neurological, ECG, and laboratory examinations; * DSM-5 criteria for Opioid Use Disorder; * Documented evidence (by urine toxicology) of opioid use (upon screening); * Inpatient verified \> 1 week of abstinence; * For females, a negative serum pregnancy (beta-HCG) test. Exclusion Criteria: * DSM-5 criteria for other substance use disorders (e.g., alcohol, cocaine, sedative hypnotics), except for nicotine (concurrent alcohol or drug use is allowed if it does not meet criteria for a…
Interventions
- DrugPsilocybin
Participants will receive a single dose of psilocybin administered in 20 mg or 25 mg doses depending on the participant's weight: 20 mg (among participants \< 70 kg) or 25 mg (among participants \>70 kg). Participants will be administered psilocybin at CNRU, within 1-2 weeks of the baseline \[11C\]-UCB-J PET.
Location
- Yale UniversityNew Haven, Connecticut